Muscle-Targeting Antibody-Oligonucleotide Complexes for FSHD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are ineffective in targeting and inhibiting the expression of the DUX4 gene in muscle cells, which is a key factor in Facioscapulohumeral Muscular Dystrophy (FSHD), leading to a lack of effective therapies for the disease.
Innovation Solution
Development of muscle-targeting complexes comprising antibodies covalently linked to molecular payloads, such as oligonucleotides, that specifically bind to muscle cells via the transferrin receptor, allowing for receptor-mediated internalization and subsequent release to inhibit DUX4 gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to target muscle cells, then delivery to non-specific cells occurs, but specific targeting of muscle cells to inhibit DUX4 expression is ineffective
Solution Approach 1:
The antibody is designed to specifically recognize and bind to the transferrin receptor expressed on muscle cell surfaces, providing localized and selective targeting. This specificity ensures that the molecular payload is delivered only to the intended muscle cells rather than non-specific cells, thereby improving both targeting precision and therapeutic effectiveness
Solution Approach 2:
The transferrin receptor serves as an intermediary structure that mediates the entry of the antibody-molecular payload complex into muscle cells. By utilizing this naturally occurring receptor, the system achieves efficient and specific cellular uptake in muscle tissue, enhancing both the precision of targeting and the reliability of DUX4 expression inhibition
2Productivity
If molecular payloads are delivered without specific targeting, then general cellular uptake occurs, but inhibition of DUX4 gene expression in muscle cells is not achieved
Solution Approach 1:
The antibody component confers muscle cell-specific recognition capability to the complex, ensuring that high delivery efficiency is achieved only at the intended target site (muscle cells). This localized specificity prevents off-target delivery while maintaining efficient uptake through the transferrin receptor pathway
Solution Approach 2:
The complex combines an antibody (for specific targeting) with a molecular payload (for gene expression inhibition) into a composite structure. This composite design integrates the specificity of the antibody with the functional activity of the payload, achieving both efficient delivery to muscle cells and effective DUX4 inhibition
3Adaptability or versatility
If non-specific delivery methods are used, then broad cellular distribution occurs, but selective modulation of DUX4 expression in muscle tissue is not achieved
Solution Approach 1:
The system employs the antibody's specific affinity for the transferrin receptor to concentrate the molecular payload exclusively in muscle tissue. This localized delivery approach sacrifices broad cellular distribution but ensures reliable disease treatment by selectively modulating DUX4 expression only in the affected muscle cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complexes effectively reduce DUX4 expression levels in muscle cells, providing a potential therapeutic approach for FSHD by selectively targeting and modulating gene activity within muscle tissue.
Implementation Method 1
the complexes are taken up into the cells via a receptor mediated internalization
Data Source
AI summary
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.